V
52.52
2.23 (4.43%)
| Previous Close | 50.29 |
| Volume | 1,834,513 |
| Price / Earnings (Forward) | 27.05 |
| Price / Sales | 7.30 |
| Price / Book | 2.91 |
| 52 Weeks Range |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Veracyte, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -0.6 |
| Price Volatility | -2.8 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | 2.4 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.46 |
Select this tab to load the latest available analysis.
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.98% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EASTHAM KARIN | - | 50.28 | -14,850 | -746,658 |
| HOLSTEIN JENS | - | 50.28 | -7,500 | -377,100 |
| WYGANT JONATHAN | - | 50.31 | -1,306 | -65,705 |
| Aggregate Net Quantity | -23,656 | |||
| Aggregate Net Value ($) | -1,189,463 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 50.28 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WYGANT JONATHAN | Officer | 28 Oct 2026 | Disposed (-) | 1,306 | 50.31 | 65,705 |
| EASTHAM KARIN | Director | 27 Oct 2026 | Automatic sell (-) | 14,850 | 50.28 | 746,658 |
| EASTHAM KARIN | Director | 27 Oct 2026 | Option execute | 10,000 | - | - |
| HOLSTEIN JENS | Director | 27 Oct 2026 | Automatic sell (-) | 7,500 | 50.28 | 377,100 |
| HOLSTEIN JENS | Director | 27 Oct 2026 | Option execute | 7,500 | - | - |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |